Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More
Pfizer’s internal obesity drug R&D stumbled, but the pharmaceutical giant is leaping ahead in this field through the multi-billion dollar ...
Pfizer’s internal obesity drug R&D stumbled, but the pharmaceutical giant is leaping ahead in this field through the multi-billion dollar ...
FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug ...
How can a biotech startup raise more than $1 billion over four plus years and say almost nothing publicly along ...
WASHINGTON — The Food and Drug Administration announced Friday that it has begun publishing reports of adverse events concerning drugs ...
Credit: Jack Botting, Yale University Non-antibiotic drugs can alter the microbiome and increase the risk of gut infections in surprising ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.LONDON — ...
A major meta-analysis finds that patients who discontinue anti-obesity medications quickly regain weight, yet, crucially, they still retain some of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
People with diabetes who were taking GLP-1 drugs had a low but elevated risk of an age-related eye disease that ...
A Kura Oncology and Kyowa Kirin-partnered drug vying to become the first FDA-approved treatment for cases of acute myeloid leukemia ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.